BIO-TECHNE TO PRESENT AT THE COWEN 42ND ANNUAL HEALTH CARE CONFERENCE

Rhea-AI Summary

Bio-Techne Corporation (NASDAQ: TECH) has announced that Executive Vice President and CFO Jim Hippel will present at the Cowen 42nd Annual Health Care Conference on March 7, 2022, at 11:10 a.m. EST. The presentation will be accessible via a live webcast on Bio-Techne's Investor Relations website. The company, a key player in the development of purified proteins and reagent solutions, recorded approximately $931 million in net sales in fiscal 2021 and employs around 2,700 staff worldwide, focusing on diagnostics and genomic tools.

MINNEAPOLIS, Feb. 28, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the Cowen 42^nd Annual Health Care Conference on Monday, March 7, 2022, at 11:10 a.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.

Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high-quality purified proteins and reagent solutions - notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, T-Cell activation and gene editing technologies. Bio-Techne's product portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, offering researchers efficient and streamlined options for automated Western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers as well as clinical research laboratories and constitute the Protein Sciences Segment. Bio-Techne also develops and manufactures diagnostic products including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and custom assay development on dedicated clinical instruments. Bio-Techne's genomic tools include advanced tissue-based in situ hybridization assays (ISH) for research and clinical use, sold under the ACD brand as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx^® Prostate test for prostate cancer diagnosis. These diagnostic and genomic products comprise Bio-Techne's Diagnostics and Genomics Segment. Bio-Techne products are integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $931 million in net sales in fiscal 2021 and has approximately 2,700 employees worldwide.

Contact:  David Clair, Senior Director, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416  

View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-to-present-at-the-cowen-42nd-annual-health-care-conference-301491238.html

SOURCE Bio-Techne Corporation

FAQ

What date will Bio-Techne present at the Cowen 42nd Annual Health Care Conference?

Bio-Techne will present on March 7, 2022.

Who will represent Bio-Techne at the Cowen 42nd Annual Health Care Conference?

Jim Hippel, Executive Vice President and CFO, will represent Bio-Techne.

What time is Bio-Techne's presentation at the Cowen 42nd Annual Health Care Conference?

The presentation is scheduled for 11:10 a.m. EST.

How can I access the Bio-Techne presentation at the conference?

The presentation will be available via a live webcast on Bio-Techne's Investor Relations website.

What is Bio-Techne's stock symbol?

Bio-Techne's stock symbol is TECH.